3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
21
Nivolumab
7
Docetaxel
7
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Trastuzumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
atezolizumab
3
Taxes
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Counseling
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
poly ICLC
2
durvalumab
2
belinostat
2
X-Rays
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled